Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE Small Cap

 325.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 470.00p
  • 52 Week Low: 166.80p
  • Currency: UK Pounds
  • Shares Issued: 100.01m
  • Volume: 0
  • Market Cap: £325.55m
  • RiskGrade: 125

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

By Frank Prenesti

Date: Wednesday 05 Jan 2022

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
The deal gives Cabaletta a non-exclusive licence for LentiVector to be used on Chimeric autoantibody receptor T programme, DSG3-CAART, for autoimmune disease.

No financial details were revealed, but Oxford Biomendica said the arrangements of the LSA were "in line with comparable deals the group has previously secured".





Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

OXB Market Data

Currency UK Pounds
Share Price 325.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 470.00p
52 Week Low 166.80p
Volume 0
Shares Issued 100.01m
Market Cap £325.55m
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
27.76% below the market average27.76% below the market average27.76% below the market average27.76% below the market average27.76% below the market average
17.65% above the sector average17.65% above the sector average17.65% above the sector average17.65% above the sector average17.65% above the sector average
Price Trend
5.28% below the market average5.28% below the market average5.28% below the market average5.28% below the market average5.28% below the market average
28.30% above the sector average28.30% above the sector average28.30% above the sector average28.30% above the sector average28.30% above the sector average
Income Not Available
Growth
52.97% below the market average52.97% below the market average52.97% below the market average52.97% below the market average52.97% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average

What The Brokers Say

Strong Buy 1
Buy 3
Neutral 5
Sell 0
Strong Sell 0
Total 9
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

OXB Key Personnel

CFO Stuart Paynter
CEO Frank Mathias

Top of Page